Details for: CL0001071

Cell ID: CL0001071

Cell Name: group 3 innate lymphoid cell

Description: An innate lymphoid cell that constituitively expresses RORgt and is capable of expressing IL17A and/or IL-22.

Synonyms: ILC3

Selected Context(s): Overall

Gene Significance Landscape

Display Options
Score:
Display
Genes

Contexts:

Cell Significance Index (CSI) is uniquely calculated to reveal cell-specific gene markers. More info here

Significant Genes List

Genes with the highest and lowest Percentile Rank Scores (PRS) for group 3 innate lymphoid cell within the selected context(s).

Gene ID: A unique numerical identifier for this specific gene.
Symbol: Shortened abbreviation or name that represents this gene.
Ensembl Gene ID: A unique identifier assigned by Ensembl for genomic data mapping.
CSI Score: A combined effect size and statistical significance measure for group 3 innate lymphoid cell. Higher scores indicate a stronger, more significant difference in expression.
(Previously described as "Fold Change", but now represents Cliff's Delta × –log10(p).)

Gene ID: A unique numerical identifier for this specific gene.
Symbol: Shortened abbreviation or name that represents this gene.
Ensembl Gene ID: A unique identifier assigned by Ensembl for genomic data mapping.
CSI Score: A combined effect size and statistical significance measure for group 3 innate lymphoid cell. Higher scores indicate a stronger, more significant difference in expression.
Average CSI: csi sum / gene count
Cell network configuration

This network visualizes key genes for group 3 innate lymphoid cell. It primarily includes:
1. Top genes highly significant for this cell (Num. Top Cell Genes - based on the 'Min. CSI' setting).
2. Any additional specific 'Context Genes' you add below.
The final network is a combined view. Choose an Interaction Source (pathways or protein interactions) and optionally compare CSI scores with a Baseline Cell Type.

Maximum number of selected genes.
Select a context for the baseline cell.
Select a context for the target cell.
Target Cell for CSI:  group 3 innate lymphoid cell (CL0001071)

 Legend
Nodes (Genes):
 Query Gene
Node size also reflects Target Cell CSI magnitude.
Node Color (Target Cell CSI in specific network):
 Very High
 High
 Medium
 Low
 Very Low
 N/A or Not Sig.
Edges (Interactions):
 STRING (Protein-Protein)
 ONTOLOGY (Shared Pathway)
 Colors vary by pathway category; default arrow applies.

Loading network (please wait)...

## Summary The [group 3 innate lymphoid cell](/details-cell/CL0001071) (ILC3) is a subset of innate lymphocytes characterized by its constitutive expression of the transcription factor RORγt and its capacity to produce effector cytokines such as IL-17A and IL-22. Based on its gene significance profile, the ILC3 is distinguished by an exceptionally high and specific expression of genes involved in protein synthesis, mRNA processing, and energy metabolism. This suggests that the cell maintains a state of heightened metabolic and biosynthetic readiness, positioning it to execute rapid and potent effector functions, particularly at mucosal barriers where it plays a critical role in immunity and tissue homeostasis. ## Key Characteristics and Function **Overall**, the gene expression signature of the [group 3 innate lymphoid cell](/details-cell/CL0001071) is dominated by genes essential for fundamental cellular processes, but their high expression specificity (high `csi_z` scores) indicates these processes are a defining feature of the cell's identity and function. These markers can be grouped into several key functional clusters: * **Protein Synthesis and RNA Processing:** A prominent feature of ILC3s is the highly specific expression of a suite of genes involved in mRNA processing, stability, and translation. This includes the poly(A)-binding protein [PABPC1](/details-gene/26986), several heterogeneous nuclear ribonucleoproteins such as [HNRNPA1](/details-gene/3178), [HNRNPA2B1](/details-gene/3181), and [HNRNPC](/details-gene/3183), and eukaryotic translation elongation factors [EEF1D](/details-gene/1936) and [EEF1B2](/details-gene/1933). The top marker, [TPT1](/details-gene/7178), is also linked to the translational machinery. This collective signature strongly suggests that ILC3s are constitutively primed to be robust protein factories, a state consistent with their role as rapid producers of inflammatory cytokines. * **High Metabolic Activity:** The cell exhibits a distinct metabolic profile characterized by high expression specificity of multiple components of the mitochondrial electron transport chain. Key markers include several cytochrome c oxidase subunits ([COX1](/details-gene/4512), [COX2](/details-gene/4513), [COX4I1](/details-gene/1327), [COX7C](/details-gene/1350)) and cytochrome b ([CYTB](/details-gene/4519)). This implies a high capacity for oxidative phosphorylation, which would be necessary to generate the ATP required to fuel its extensive biosynthetic activities and sustain effector functions. The co-expression of ferritin heavy and light chains ([FTH1](/details-gene/2495) and [FTL](/details-gene/2512)) further supports this, indicating a robust system for managing iron, a critical cofactor for metabolic enzymes. * **Antigen Presentation and Immune Interaction:** The high significance of Beta-2-microglobulin ([B2M](/details-gene/567)), an essential component of MHC class I molecules, is notable for an innate lymphoid cell. This suggests that ILC3s may have the capacity to present endogenous antigens to [CD8-positive, alpha-beta T cells](/details-cell/CL0000625), potentially enabling them to interact with and modulate adaptive immune responses. The profile of anti-markers is also informative. The low significance score for transcription factors like [GFI1](/details-gene/2672), which is involved in broader hematopoietic development, suggests that the unique identity of ILC3s is less defined by the specific expression of such general lineage factors and more by their master regulators (e.g., RORγt) and the downstream effector machinery highlighted in the top markers. ## Clinical Significance and Contextual Roles While the provided data is an **Overall** summary without a specific disease context, the inherent characteristics of the [group 3 innate lymphoid cell](/details-cell/CL0001071) gene signature have significant clinical implications. ILC3s are key players at mucosal surfaces, such as the gut and skin, and are implicated in both protective immunity against extracellular pathogens and the pathology of chronic inflammatory and autoimmune diseases. The cell's apparent state of being "primed for action," with its highly active protein synthesis and metabolic machinery, explains its ability to respond rapidly to environmental triggers. This rapid response is crucial for maintaining barrier integrity but can become dysregulated in disease. In conditions like inflammatory bowel disease (IBD) or psoriasis, hyperactivation of ILC3s can lead to excessive production of IL-17 and IL-22, driving tissue inflammation and damage. The genes identified here, particularly those controlling translation and metabolic flux, represent potential nodes for therapeutic intervention aimed at dampening ILC3 effector function without complete ablation of the cell type. Furthermore, the high expression of [B2M](/details-gene/567) may point to a role in interacting with T cells within inflamed tissues, potentially contributing to the persistence of chronic inflammation. ## Potential Mechanisms and Research Directions 1. **Hypothesis:** The defining characteristic of [group 3 innate lymphoid cells](/details-cell/CL0001071) is a state of "post-transcriptional preparedness." The high and specific expression of a broad suite of genes for mRNA processing ([PABPC1](/details-gene/26986), [HNRNPA1](/details-gene/3178)), transport, and translation ([EEF1D](/details-gene/1936), [EEF1B2](/details-gene/1933)) allows the cell to maintain a pool of poised cytokine mRNAs (e.g., *IL17A*, *IL22*) that can be translated immediately upon stimulation, enabling a faster response than that allowed by de novo transcription. * **Surprising Findings:** The most specific markers for ILC3s are not the effector cytokines themselves but rather the universal cellular machinery required to produce them. This suggests that the *capacity* for rapid protein production, rather than the basal expression of the final product, is the most unique feature of the ILC3 transcriptional program. * **Testable Questions:** Does analysis of polysome-bound RNA in resting ILC3s reveal pre-loaded, untranslated transcripts for key effector cytokines? Furthermore, would treatment with translation inhibitors like cycloheximide have a more profound and immediate blocking effect on ILC3 cytokine secretion compared to transcription inhibitors like actinomycin D during the initial hours after activation? 2. **Hypothesis:** The metabolic identity of ILC3s, defined by a constitutively high capacity for oxidative phosphorylation (as suggested by high expression of [COX1](/details-gene/4512), [COX2](/details-gene/4513), and [CYTB](/details-gene/4519)), is a critical determinant of their effector function. This elevated metabolic baseline, coupled with robust iron management ([FTH1](/details-gene/2495), [FTL](/details-gene/2512)), is essential to meet the bioenergetic demands of rapid cytokine synthesis and may serve as a key regulatory checkpoint. * **Surprising Findings:** Many immune cells undergo a metabolic shift to aerobic glycolysis (the Warburg effect) upon activation to support rapid biosynthesis. The strong, defining signature of oxidative phosphorylation components in ILC3s suggests they may rely on this more efficient energy pathway even during their initial effector phase, or that this high basal respiratory capacity is a prerequisite for any subsequent metabolic reprogramming. * **Testable Questions:** Using metabolic flux analysis, do resting ILC3s exhibit a higher basal oxygen consumption rate (OCR) and spare respiratory capacity compared to other resting lymphocyte populations (e.g., naive T cells)? Does targeted pharmacological inhibition of the electron transport chain (e.g., with rotenone or antimycin A) block the primary effector cytokine response of ILC3s to stimuli like IL-23?